Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment op...

Descripción completa

Detalles Bibliográficos
Autor principal: Sims, Robert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119403/
https://www.ncbi.nlm.nih.gov/pubmed/21716715
_version_ 1782206565774786560
author Sims, Robert B.
author_facet Sims, Robert B.
author_sort Sims, Robert B.
collection PubMed
description Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population.
format Online
Article
Text
id pubmed-3119403
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-31194032011-06-28 Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Sims, Robert B. J Cancer Short Report Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population. Ivyspring International Publisher 2011-06-15 /pmc/articles/PMC3119403/ /pubmed/21716715 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Short Report
Sims, Robert B.
Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
title Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
title_full Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
title_fullStr Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
title_full_unstemmed Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
title_short Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
title_sort sipuleucel-t: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119403/
https://www.ncbi.nlm.nih.gov/pubmed/21716715
work_keys_str_mv AT simsrobertb sipuleuceltautologouscellularimmunotherapyformenwithasymptomaticorminimallysymptomaticmetastaticcastrateresistantprostatecancer

Ejemplares similares